Back to search

Article

Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease

2025-02-21

Abstract excerpt

<h4>Summary</h4> Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated wi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9a3de7e7-5448-52e8-bd2c-0cbded8130b6
DOI
10.1101/2025.02.18.25321035
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseDOI 10.1101/2025.02.18.25321035
Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity
Pharmaceutical Repurposing Strategies for Metabolic Disorders: Insights from Mendelian Randomization StudiesSemantic proximity
Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity
Cross-trait genomic modeling reveals the polygenic architecture and systemic impact of MASLD.Semantic proximity
Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver DiseaseSemantic proximity
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.Semantic proximity
Integrative multi-omics and multi-trait analysis prioritizes regulatory mechanisms and genes for metabolic dysfunction-associated steatotic liver diseaseSemantic proximity
Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical applicationSemantic proximity
Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External ValidationSemantic proximity
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.Semantic proximity
Prioritization of therapeutic targets for dyslipidemia using integrative multi-omics and multi-trait analysis.Semantic proximity
Human genetics of metabolic dysfunction–associated steatotic liver disease: from variants to cause to precision treatmentSemantic proximity
Select a neighboring publication to make it the new centre.